Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC.24: The LIBerate-CVD Trial
Author(s): Evan A Stein Added: 1 week ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
Effect of Japanese Guideline on Lipids and Coronary Events in ACS
Author(s): Ryotaro Yamada , Teruyoshi Kume , Hiroshi Okamoto , et al Added: 2 years ago

Standards & Guidelines
Vera Bittner
Job title: Professor / Section Head, General Cardiology, Prevention and Imaging
Dr Vera Bittner, MD, MSPH, is Professor of Medicine at the University of Alabama at Birmingham and Section Head of General Cardiology, Prevention, and Imaging in the Division of Cardiovascular Disease. Dr Bittner also serves as Medical Director of the Coronary Care Unit and the University Hospital Cardiac Rehabilitation Program. Most of her research has focused on secondary prevention of… View more
ACC.24: Late-Breaking Science Video Collection
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 week ago
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA)… View more

Heart Failure

MI/ACS
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 6 months ago Source:  AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals. Among the event’s highlights are eight late-breaking trial sessions, as listed below. Watch our coverage of… View more
Acute Decompensated HFpEF: Do the Asian Phenotypes Fit?
Author(s): Raja Ezman Raja Shariff , Hui Beng Koh , Maizatu Akma Sulong , et al Added: 1 year ago

Heart Failure
MACE Risk Prediction by Machine Learning
Author(s): Fang He , John H Page , Jesisca Tandi , et al Added: 9 months ago

MI/ACS
Lipoprotein(a) and Cardiovascular Disease
Author(s): Yoshiyasu Minami , Daisuke Kinoshita , Yusuke Muramatsu , et al Added: 1 year ago

Vascular Disease and Surgery
APSC Consensus Recommendations on Secondary Prevention of MI
Author(s): Jamshed J Dalal , Wael Almahmeed , Rungroj Krittayaphong , et al Added: 1 year ago

Standards & Guidelines

Prevention & Chronic Conditions
ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)
Author(s): Steven E Nissen Added: 2 years ago
In this short summary interview, Dr Steven E Nissen (Cleveland Clinic, Cleveland, US) talks about detailed results from the APOLLO study (NCT01960348). This placebo-controlled double-blind dose-ranging trial investigated the safety and tolerability of SLN360 (Silence Therapeutics plc) in patients with elevated lipoprotein(a). Discussion Points: Trial Rationale Mechanism of Action Study… View more

Prevention & Chronic Conditions